ArticleClinical case reports2026
PLA2R-Positive Membranous Nephropathy and AA Amyloidosis in an Ethiopian Patient With Chronic Hepatitis B: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coexistence of primary phospholipase A2 receptor positive membranous nephropathy and AA amyloidosis in a patient with chronic hepatitis B is an exceedingly rare triad presenting a profound diagnostic and therapeutic challenge. A 38-year-old Ethiopian man with nephrotic syndrome and chronic hepatitis B had dual pathology on renal biopsy. Despite concurrent hepatitis B, C1q negativity and IgG4/PLA2R dominance favored a primary autoimmune process over viral-associated secondary glomerulonephritis. Immunosuppressive therapy (rituximab then cyclophosphamide) achieved complete immunological remission with loss of glomerular PLA2R antigen, yet the patient had persistent heavy proteinuria. Repeat renal biopsy determined that residual proteinuria reflected irreversible structural damage rather than active autoimmune injury. This damage included increased segmentally sclerosed glomeruli (from 11% to 33.3%) with permanent disruption of the filtration barrier from residual amyloid deposits and fibrosis. In multiple pathology settings, outcomes depend on the independent progression of each disease process. Thus, an integrated approach combining longitudinal serology and histological follow-up is essential for managing such complex cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.